Definium Therapeutics, Inc. Market Cap ($4.49 Billion)
Market Cap & Net Worth: Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. market cap. Definium Therapeutics, Inc. (NASDAQ:DFTX) has a market capitalization of $4.49 Billion ($4.49 Billion) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3715 globally and #1334 in its home market, demonstrating a -6.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Definium Therapeutics, Inc.'s stock price $33.41 by its total outstanding shares 134366950 (134.37 Million). Also see Definium Therapeutics, Inc. operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Definium Therapeutics, Inc. Market Cap History (2026–2026)
Definium Therapeutics, Inc. market cap history from 2026 to 2026. Data shows growth from $4.49 Billion to $4.49 Billion (0.00% CAGR). Check latest Definium Therapeutics, Inc. stock price today for real-time trading data and today's change.
Definium Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Definium Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore DFTX shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DFTX by Market Capitalization
Companies near Definium Therapeutics, Inc. in the global market cap rankings as of November 4, 2026. Also see Definium Therapeutics, Inc. assets under control for a full breakdown of the balance sheet.
Key companies related to Definium Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Definium Therapeutics, Inc. (2026–2026)
Market capitalization of Definium Therapeutics, Inc. from 2026 to today. Between 2026 and today, Definium Therapeutics, Inc.'s market cap moved from $4.49 Billion to $ 4.49 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Definium Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.49 Billion USD |
| MoneyControl | $4.49 Billion USD |
| MarketWatch | $4.49 Billion USD |
| marketcap.company | $4.49 Billion USD |
| Reuters | $4.49 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more